41740-17-4

Basic information

• Product Name: 6-aMino-2-phenyl-4(1H)-PyriMidinone
• Synonyms: 6-aMino-2-phenyl-4(1H)-PyriMidinone;6-amino-2-phenyl-1H-pyrimidin-4-one;6-amino-2-phenyl-4(3H)-Pyrimidinone
• CAS NO: 41740-17-4
• Molecular Formula: C₁₀H₉N₃O
• Molecular Weight: 187.19796
• Mol File: 41740-17-4.mol
• Article Data: 2

Chemical Properties

• Melting Point: 252 °C
• Boiling Point: 334.0±45.0 °C(Predicted)
• Appearance: /
• Density: 1.33±0.1 g/cm3(Predicted)
• PKA: 9.46±0.50(Predicted)
• CAS DataBase Reference: 6-aMino-2-phenyl-4(1H)-PyriMidinone(CAS DataBase Reference)
• NIST Chemistry Reference: 6-aMino-2-phenyl-4(1H)-PyriMidinone(41740-17-4)
• EPA Substance Registry System: 6-aMino-2-phenyl-4(1H)-PyriMidinone(41740-17-4)

Safety Data

• Hazardous Substances Data: 41740-17-4(Hazardous Substances Data)

Upstream product

• 1670-14-0 benzamidine monohydrochloride 
• 105-56-6 ethyl 2-cyanoacetate 
• 64-17-5 ethanol 
• 618-39-3 benzamidin 
• 18852-51-2 sodium cyanoacetic acid ethyl ester 
• 95642-58-3 4-chloro-2-phenyl-6H-1,3-thiazin-6-one 

Downstream Products

• 61595-45-7 5,6-diamino-2-phenyl-3H-pyrimidin-4-one 
• 23120-10-7 2-phenylpteridin-4(3H)-one 
• 23119-97-3 6,7-dimethyl-2-phenyl-3H-pteridin-4-one 
• 91330-73-3 2-phenyl-5,8-dihydro-3H-pteridine-4,6,7-trione 
• 31937-01-6 6-methylamino-2-phenyl-3H-pyrimidin-4-one 
• 31575-76-5 6-morpholin-4-yl-5-nitro-2-phenyl-3H-pyrimidin-4-one 
• 83717-95-7 1-Methyl-2-phenyl-4-(4'-methylphenylsulfonyloxyacetamido)pyrimidin-6-one 
• 83717-91-3 Formic acid (1-methyl-6-oxo-2-phenyl-1,6-dihydro-pyrimidin-4-ylcarbamoyl)-methyl ester 
• 83717-92-4 4-Hydroxyacetamido-1-methyl-2-phenylpyrimidin-6-one 
• 83717-85-5 4-Bromoacetamido-1-methyl-2-phenylpyrimidin-6-one 
• 83717-84-4 4-Chloroacetamido-1-methyl-2-phenylpyrimidin-6-one 
• 83717-99-1 6-Chloroacetamido-2-phenyl-3H-pyrimidin-4-one 
• 83717-81-1 4-Amino-1-methyl-2-phenylpyrimidin-6-one 
• 83718-01-8 5-Phenyl-3H-imidazo<1,2-c>pyrimidine-2,7(4H)-dione 

Relevant articles and documents

SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE

The present invention relates to pyridines, pyrimidines and derivatives thereof, and pharmaceutically acceptable salts thereof. Also included is a method of treatment of inflammation, rheumatoid arthritis, Pagets disease, osteoporosis, multiple myeloma, uveititis, acute or chronic myelogenous leukemia, pancreatic beta cell destruction, osteoarthritis, rheumatoid spondylitis, gouty arthritis, inflammatory bowel disease, adult respiratory distress syndrome (ARDS), psoriasis, Crohn's disease, allergic rhinitis, ulcerative colitis, anaphylaxis, contact dermatitis, asthma, muscle degeneration, cachexia, Reiter's syndrome, type I diabetes, type II diabetes, bone resorption diseases, graft vs. host reaction, Alzheimer's disease, stroke, myocardial infarction, ischemia reperfusion injury, atherosclerosis, brain trauma, multiple sclerosis, cerebral malaria, sepsis, septic shock, toxic shock syndrome, fever, myalgias due to HIV-1, HIV-2, HIV-3, cytomegalovirus (CMV), influenza, adenovirus, the herpes viruses or herpes zoster infection in a mammal comprising administering an effective amount a compound as described above.